Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

HDAC1 acts as a tumor suppressor in ALK-positive anaplastic large cell lymphoma: implications for HDAC inhibitor therapy

Leukemia(2025)10.1038/s41375-025-02584-9Source: DataRank Database

HDAC1 acts as a tumor suppressor in ALK-positive anaplastic large cell lymphoma: implications for HDAC inhibitor therapy is a research paper published in Leukemia (2025). On theSindex it has a DataRank of 0. It has been cited 7 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access7 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (10 grants)OA: hybridTopics (25)IDs (PubMed, PMC)Annotations (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (19)

Kristina Draganić ORCID,Anna Malzer ORCID,Verena Doblmayr,Katarina Mišura ORCID,Rafael de Freitas e Silva ORCID

Live enrichment

PubMed:40175628 PMC:PMC12133565

Austrian Science Fund

Grant: 10.55776/I4066

Austrian Science Fund

Grant: 10.55776/P32771

Austrian Science Fund

Grant: 10.55776/F8300

Austrian Science Fund

Grant: I 4066

Austrian Science Fund

Grant: SFB F83

Austrian Science Fund

Grant: 32771

EC | Horizon 2020 Framework Programme

Grant: 101072735

Future of ALCL: Novel Therapies, Origins, Bio-Markers and Mechanism of resistance

Foundation for the National Institutes of Health

Grant: R01 CA196703-01

NCI NIH HHS

Grant: R01 CA196703

National Institutes of Health

Grant: 5R01CA196703-09

Mechanisms of resistance to ALK inhibitors in ALK-rearranged lymphoma

hybridLicense: CC BY

publisherhttps://www.nature.com/articles/s41375-025-02584-9.pdf

publisherhttps://www.nature.com/articles/s41375-025-02584-9

Europe_PMChttps://europepmc.org/articles/PMC12133565

Europe_PMChttps://europepmc.org/articles/PMC12133565?pdf=render

https://doi.org/10.1038/s41375-025-02584-9

Fields of Study

03 medical and health sciences0302 clinical medicine

MeSH Terms

AnimalsHumansMiceBenzamidesPyridinesGenes, Tumor SuppressorLymphoma, Large-Cell, AnaplasticHistone Deacetylase 1Histone Deacetylase 2Histone Deacetylase InhibitorsAnaplastic Lymphoma Kinase

Keywords

PyridinesHistone Deacetylase 2Histone Deacetylase 1ArticleHistone Deacetylase InhibitorsMiceBenzamidesAnimalsLymphoma, Large-Cell, AnaplasticHumansAnaplastic Lymphoma KinaseGenes, Tumor Suppressor

HDAC1 acts as a tumor suppressor in ALK-positive anaplastic large cell lymphoma: implications for HDAC inhibitor therapy

FAIR Checklist

Authors (19)

Funding (10 grants)

Open Access

Topics

Annotations (Europe PMC)